Moderna

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Moderna and other ETFs, options, and stocks.

About MRNA

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid (mRNA). Its product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, and systemic intracellular therapeutics.

CEO

Stéphane Bancel

CEOStéphane Bancel

Employees

5,600

Employees5,600

Headquarters

Cambridge, Massachusetts

HeadquartersCambridge, Massachusetts

Founded

2010

Founded2010

Employees

5,600

Employees5,600

MRNA Key Statistics

Market cap

41.67B

Market cap41.67B

Price-Earnings ratio

-8.77

Price-Earnings ratio-8.77

Dividend yield

—

Dividend yield—

Average volume

2.56M

Average volume2.56M

High today

$113.93

High today$113.93

Low today

$106.64

Low today$106.64

Open price

$111.00

Open price$111.00

Volume

3.41M

Volume3.41M

52 Week high

$142.79

52 Week high$142.79

52 Week low

$62.55

52 Week low$62.55

MRNA News

Benzinga 17h

Moderna Stock Jumps On Collaboration With OpenAI: What's Going On?

Loading... Loading... Moderna Inc MRNA shares are trading higher Wednesday after the company announced an ongoing collaboration with OpenAI. What To Know: Mod...

Seeking Alpha 17h

Moderna and OpenAI in pact to fast-track drug development

Messenger RNA-based vaccine developer Moderna (NASDAQ:MRNA) has partnered with OpenAI to deploy San Francisco-based AI firm's ChatGPT Enterprise across its busi...

Benzinga 1d

Moderna Faces Pfizer, BioNTech in London Patent Battle over Covid-19 Vaccines In Legal Showdown

Loading... Loading... Moderna Inc. MRNA is set to clash with Pfizer Inc. PFE and BioNTech SE BNTX in a pivotal London patent trial concerning the development o...

Analyst ratings

48%

of 25 ratings

Buy

48%

Hold

40%

Sell

12%

More MRNA News

Seeking Alpha 2d

Moderna Investors Should Beware Patent-Dispute Fallout - Seeking Alpha

carmengabriela Shares in Moderna (NASDAQ:MRNA), maker of the breakthrough mRNA shot against Covid-19, jumped to a three-month high this month [April 2024] afte...

Seeking Alpha 2d

Moderna stock closes in green after eight sessions of losses

Moderna (NASDAQ:MRNA) closed in green and snapped an eight-day losing streak after having lost 4% over the last eight trading sessions. Shares of the pharmaceu...

Simply Wall St 3d

Moderna, Inc.'s Prospects Need A Boost To Lift Shares - Simply Wall St

With a price-to-sales (or "P/S") ratio of 5.7x Moderna, Inc. ( ) may be sending very bullish signals at the moment, given that almost half of all the Biotechs c...

Yahoo Finance 4d

Insiders At Moderna Sold US$3.3m In Stock, Alluding To Potential Weakness - Yahoo Finance

In the last year, many Moderna, Inc. (NASDAQ:MRNA) insiders sold a substantial stake in the company which may have sparked shareholders' attention. Knowing whet...

Yahoo Finance 5d

Moderna Stock Moves -0.58%: What You Should Know - Yahoo Finance

The latest trading session saw Moderna (MRNA) ending at $101.41, denoting a -0.58% adjustment from its last day's close. The stock's change was more than the S&...

Seeking Alpha 5d

Moderna stock on track for the eighth consecutive day of losses - Seeking Alpha

Moderna (NASDAQ:MRNA) shares are trading in the red on Friday, on track for the eighth consecutive day of losses. Stock down 1.28% at $100.70. MRNA has lost ab...

Investor's Business Daily 6d

Analysts Expect Moderna's First-Quarter Sales To Plummet 95% — Is Moderna Stock A Sell?

Moderna (MRNA) stock surged — and then tumbled — in mid-April after the company unveiled early-stage test results for its Merck (MRK)-partnered cancer vaccine....